Pharming Group (NASDAQ:PHAR) Short Interest Update

Pharming Group (NASDAQ:PHAR) saw a significant drop in short interest during the month of February. As of February 28th, there was short interest totalling 2,800 shares, a drop of 47.2% from the February 13th total of 5,300 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily volume of 7,100 shares, the short-interest ratio is presently 0.4 days.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its position in Pharming Group (NASDAQ:PHAR) by 16.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 47,997 shares of the company’s stock after purchasing an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 as of its most recent SEC filing. Institutional investors own 0.03% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on PHAR shares. HC Wainwright reaffirmed a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a research report on Friday. Jefferies Financial Group began coverage on Pharming Group in a report on Monday, December 9th. They issued a “buy” rating and a $14.00 target price on the stock. Finally, Oppenheimer upped their price target on Pharming Group from $30.00 to $39.00 and gave the stock an “outperform” rating in a report on Friday.

Pharming Group Price Performance

Shares of PHAR stock traded up $0.03 during trading hours on Friday, hitting $8.77. 2,836 shares of the company’s stock were exchanged, compared to its average volume of 6,183. The stock’s 50-day moving average is $8.99 and its 200-day moving average is $8.58. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. Pharming Group has a 52 week low of $6.65 and a 52 week high of $11.80. The stock has a market cap of $596.63 million, a price-to-earnings ratio of -33.73 and a beta of -0.10.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings data on Thursday, March 13th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.02). Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. The company had revenue of $92.70 million during the quarter, compared to analyst estimates of $76.67 million. As a group, research analysts forecast that Pharming Group will post -0.2 EPS for the current year.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.